A group representing independent pharmacies is urging Congress to cut the deficit by reducing healthcare expenditures, but “without compromising patients’ access to their pharmacy of choice or harming local jobs.”
The National Community Pharmacists Association on Tuesday released results from a survey of more than 800 independent community pharmacists about the negative consequences for their patients and their businesses if diabetes testing supplies under Medicare Part B are subjected to competitive bidding prices.
Drug makers have 901 biotech drugs under development for more than 100 diseases ranging from cancers and infectious diseases to autoimmune disorders and cardiovascular diseases, the Pharmaceutical Research and Manufacturers of America said.
The debate on the prescription status of pseudoephedrine in the state of Kentucky heated up last week as the deputy director of the White House Office of National Drug Control Policy Benjamin Tucker on Wednesday told Kentucky lawmakers that they should mandate PSE to Rx-only status, according to reports.
AccuDial Pharmaceutical on Tuesday acquired Stephen Key Design in a move that will expand AccuDial’s patent portfolio to more than 50 patents for weight-based dosing and other extended content rotating labels, which add 75% more labeling space to a container.
The National Community Pharmacists Association is recommending several ways for reducing Medicare Part D fraud, waste and abuse to the Senate Homeland Security and Government Affairs subcommittee, the group said Tuesday.
Though his term as Generic Pharmaceutical Association president and CEO began four weeks ago, Ralph Neas made his big debut Tuesday as he delivered his remarks at the GPhA-Food and Drug Administration Fall Technical Conference.
A wave of patent expirations over the next several years will open up a broad swath of drugs to generic competition, and India's Lupin Pharmaceuticals is looking to benefit, according to published reports.
Sun Pharmaceutical Industries last month said that it has resolved issues cited in a warning letter sent to the company by the Food and Drug Administration pertaining to one of Sun Pharma's U.S.-based manufacturing facilities.